BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Belantamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Belantamab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07742527-3313@assetmemo.bio
DTSTAMP:20261121T004532Z
DTSTART;VALUE=DATE:20270805
DTEND;VALUE=DATE:20270806
SUMMARY:Belantamab: Phase 1 readout est. (NCT07742527)
DESCRIPTION:Belantamab\, phase 1\, Multiple Myeloma.\nStudy: A Study to Eva
 luate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous B
 elantamab in Participants With Multiple Myeloma While Treated With Standar
 d of Care\nEstimated primary completion: 5 August 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/belantamab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07742527
URL:https://assetmemo.bio/drug/belantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714839-3313@assetmemo.bio
DTSTAMP:20261121T004532Z
DTSTART;VALUE=DATE:20280803
DTEND;VALUE=DATE:20280804
SUMMARY:Belantamab: Phase 1/2 readout est. (NCT05714839)
DESCRIPTION:Belantamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to I
 nvestigate the Safety and Efficacy of Belantamab for the Treatment of Mult
 iple Myeloma When Used as Monotherapy and in Combination Treatments\nEstim
 ated primary completion: 3 August 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/belantamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05714839
URL:https://assetmemo.bio/drug/belantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
